For example, loss-of-function mutations in tumor suppressor genes have been shown to predict a lack of sensitivity to BRAF-targeted therapy and are negatively associated with survival outcomes in melanoma.12-15 By contrast, in colorectal cancer (CRC), loss-of-function mutations in specific tumor suppressor genes have been proposed to predict good response to BRAF-targeted therapy and improved survival.16,17 Generally, the impact of molecular coalterations regarding response and outcomes to BRAF-targeted therapy has yet to be fully elucidated. The gene discussed is BRAF; the disease is melanoma.